Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $51.00 at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective increased by HC Wainwright from $49.00 to $51.00 in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2024 earnings at ($1.11) EPS, FY2024 earnings at ($3.75) EPS, FY2025 earnings at ($3.76) EPS and FY2026 earnings at ($2.98) EPS.

A number of other equities analysts have also recently weighed in on the stock. Bank of America upped their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Citigroup raised their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 16th. The Goldman Sachs Group boosted their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Barclays raised their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.64.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX opened at $15.60 on Monday. The company has a market capitalization of $1.33 billion, a PE ratio of -4.30 and a beta of 0.92. The company’s fifty day moving average price is $18.71 and its 200 day moving average price is $20.08. Syndax Pharmaceuticals has a 1 year low of $15.00 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the prior year, the company posted ($0.73) EPS. On average, equities analysts expect that Syndax Pharmaceuticals will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in Syndax Pharmaceuticals by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after buying an additional 66,459 shares in the last quarter. Barclays PLC increased its position in shares of Syndax Pharmaceuticals by 143.4% during the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after acquiring an additional 110,535 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in Syndax Pharmaceuticals by 319.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock valued at $1,565,000 after purchasing an additional 61,916 shares during the period. Two Sigma Advisers LP grew its stake in Syndax Pharmaceuticals by 7.7% during the 3rd quarter. Two Sigma Advisers LP now owns 669,352 shares of the company’s stock worth $12,885,000 after purchasing an additional 48,100 shares in the last quarter. Finally, Sphera Funds Management LTD. increased its holdings in Syndax Pharmaceuticals by 25.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock worth $19,921,000 after purchasing an additional 212,799 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).